Market capitalization | HKD63.04b |
Enterprise Value | HKD201.09b |
P/E (TTM) P/E ratio | 6.73 |
EV/FCF (TTM) EV/FCF | 11.76 |
EV/Sales (TTM) EV/Sales | 0.31 |
P/S ratio (TTM) P/S ratio | 0.10 |
P/B ratio (TTM) P/B ratio | 0.78 |
Dividend yield | 4.72% |
Last dividend (FY23) | HKD0.96 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
16 Analysts have issued a Sinopharm Group forecast:
16 Analysts have issued a Sinopharm Group forecast:
Jun '24 |
+/-
%
|
||
Revenue | 638,741 638,741 |
4%
4%
|
|
Gross Profit | 50,644 50,644 |
8%
8%
|
|
EBITDA | 27,069 27,069 |
9%
9%
|
EBIT (Operating Income) EBIT | 22,031 22,031 |
12%
12%
|
Net Profit | 9,361 9,361 |
7%
7%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic of China. It operates through the following business segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers and other suppliers. The Medical Devices segment consists of the distribution of medical devices in China. The Retail Pharmacy segment refers to the network of retail drug stores in major cities of China via direct operations and franchises. The Other Business segment comprises of the production and sale of pharmaceutical products, chemical reagents and laboratory supplies. The company was founded on January 8, 2003 and is headquartered in Shanghai, China.
Head office | China |
Employees | 115,959 |
Founded | 2003 |
Website | ir.sinopharmgroup.com.cn |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.